Nussbaum Ran 4/A
4/A · UroGen Pharma Ltd. · Filed Feb 28, 2023
Insider Transaction Report
Form 4/AAmended
Nussbaum Ran
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-10-21−15,276→ 0 total(indirect: By Partnership)Exercise: $5.94From: 2018-12-27Exp: 2022-12-27→ Ordinary Shares (15,276 underlying) - Exercise/Conversion
Ordinary Shares
2022-10-21$5.94/sh+47,999$285,114→ 1,485,168 total(indirect: Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd) - Exercise/Conversion
Stock Option (right to buy)
2022-10-21−32,723→ 0 total(indirect: By Partnership)Exercise: $5.94From: 2018-12-27Exp: 2022-12-27→ Ordinary Shares (32,723 underlying)
Footnotes (1)
- [F1]On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares.